Evidence map›Paper›PMID 41145842›Full record

ArticleNPJ precision oncology2025

ZEB1 and ALKBH5 coregulate CRABP2 and FABP5 and jointly determine the sensitivity of anaplastic thyroid cancers to gemcitabine and retinoic acid.

Xiaoting Tian, Kunlun Peng, Tianlei Zhao, Bin Jia, Qinghe Ma, Yayou Miao, Suyang Yang, Jiao Wu, Lifang Ma, Dongwei Su and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaoting Tian *Department of Clinical Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Kunlun Peng *Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Tianlei Zhao *Department of Thyroid and Breast Surgery, Navy Medical Center of PLA, Shanghai, China.
Bin Jia *Liaoning Laboratory of Cancer Genetics and Epigenetics and Department of Cell Biology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Qinghe MaShanghai United International School (Gubei Campus), Shanghai, China.
Yayou MiaoShanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Suyang YangShanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jiao WuLiaoning Laboratory of Cancer Genetics and Epigenetics and Department of Cell Biology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Lifang MaDepartment of Clinical Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. malifang0606118@126.com.
Dongwei SuDepartment of Thyroid and Breast Surgery, Navy Medical Center of PLA, Shanghai, China. sudongwei@126.com.
Xiao ZhangShanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 728002276@shsmu.edu.cn.

Funding

Excellent Talents Nurture Project of Shanghai Chest Hospital 2021YNZYY01Shanghai Rising-Star Program 22QA1408300Shanghai Rising-Star Program 22QA1408400
6 · The paper itself

Abstract

Retinoic acid (RA) signaling through CRABP2 and FABP5 differentially influences therapeutic responses and drug resistance in anaplastic thyroid cancer (ATC), yet regulatory mechanisms remain unclear. Our study reveals low CRABP2 and high FABP5 expression in ATC cell lines (THJ-11T/16T/21T), with RA alone showing no growth inhibition but RA/gemcitabine (GEM) combination exhibiting synergistic effects. ZEB1 transcriptionally regulates both proteins, where RA/GEM treatment alters its promoter binding pattern-reducing FABP5 association while enhancing CRABP2 binding. Co-regulators KAT2B and EP300 compete for ZEB1's CP domain during transcriptional regulation. Notably, RA/GEM modulates m

Identifiers

PMID41145842
PMCPMC12559330

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.